Gastric motor and sensory function

Current Opinion in Gastroenterology

Volumn 25, Issue 6, 2009, Pages 557-565

  Tack, Jan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Gastric accommodation; Gastric emptying; Gastric sensitivity

Indexed keywords

ACOTIAMIDE; AMITRIPTYLINE; APREPITANT; ASIMADOLINE; BOTULINUM TOXIN; CATECHOL METHYLTRANSFERASE; CYCLOOXYGENASE 1; DOMPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUPENTIXOL; GHRELIN; GUANINE NUCLEOTIDE BINDING PROTEIN BETA 3; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; ITOPRIDE; MELITRACEN; MIRTAZAPINE; MITEMCINAL; NORTRIPTYLINE; OPIATE AGONIST; PLACEBO; PROKINETIC AGENT; SEROTONIN 1A AGONIST; SEROTONIN 4 AGONIST; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; TZP 101; UNCLASSIFIED DRUG; VENLAFAXINE;

ATOPY; AUTONOMIC DYSFUNCTION; BACTERIAL INFECTION; BREATH ANALYSIS; CHEMOSENSITIVITY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DEVICE; DIABETIC NEUROPATHY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROGASTROGRAPHY; ELECTROSTIMULATION; GASTROENTERITIS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; HYPERSENSITIVITY; INTERSTITIAL CELL OF CAJAL; ISCHEMIA; LIPID DIET; MILK ALLERGY; NAUSEA AND VOMITING; NITRERGIC NERVE; NONHUMAN; PATHOGENESIS; PSYCHOSOCIAL DISORDER; REVIEW; SENSORIMOTOR FUNCTION; SMARTPILL; STOMACH EMPTYING; STOMACH MOTILITY; STOMACH PARESIS; STOMACH SCINTISCANNING; TEST MEAL; VISCERAL HYPERSENSITIVITY;

CLINICAL TRIALS AS TOPIC; CRITICAL ILLNESS; DYSPEPSIA; GASTRIC EMPTYING; GASTROPARESIS; HUMANS; NUTRITIONAL SUPPORT; STOMACH;

EID: 74549165581     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328331b5ad     Document Type: Review

References (95)

1. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130:1466-1479.
2. Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 2006; 18:263-283.
3. Tack J. Gastric motor disorders. Best Pract Res Clin Gastroenterol 2007; 21:633-644.
4. Mimidis K, Tack J. Pathogenesis of dyspepsia. Dig Dis 2008; 26:194-202.
5. Wang YR, Fisher RS, Parkman HP. Gastroparesis-related hospitalizations in the United States: trends, characteristics, and outcomes, 1995-2004. Am J Gastroenterol 2008; 103:313-322. The first report on time trends in hospitalizations for gastroparesis.
6. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127:1239-1255.
7. Abell TL, Camilleri M, Donohoe K, et al., American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol 2008; 103:753-763. Important effort in the standardization of radionuclide gastric emptying testing.
8. Perri F, Pastore MR, Annese V. 13C-octanoic acid breath test for measuring gastricemptyingof solids.Eur Rev Med Pharmacol Sci 2005;9(5Suppl 1):3-8.
9. Szarka LA, Camilleri M, Vella A, et al. A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin Gastroenterol Hepatol 2008; 6:635e1-643e1.
10. Kuo B, McCallum RW, Koch KL, et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther 2008; 27:186-196.
11. Cassilly D, Kantor S, Knight LC, et al. Gastric emptying of a nondigestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphy. Neurogastroenterol Motil 2008; 20:311-319. The first report on clinical application of a novel wireless capsule device for the assessment of gastrointestinal motor function.
12. Camilleri M, Bharucha AE, di Lorenzo C, et al. American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice. Neurogastroenterol Motil 2008; 20:1269-1282.
13. Sha W, Pasricha PJ, Chen JD. Rhythmic and spatial abnormalities of gastric slow waves in patients with functional dyspepsia. J Clin Gastroenterol 2009; 43:123-129.
14. Krusiec-Swidergol B, Jonderko K. Multichannel electrogastrography under a magnifying glass: an in-depth study on reproducibility of fed state electrogastrograms. Neurogastroenterol Motil 2008; 20:625-634.
15. Kindt S, Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 2006; 55:1685-1691.
16. Tutuian R, Vos R, Karamanolis G, Tack J. An audit of technical pitfalls of gastric barostat testing in dyspepsia. Neurogastroenterol Motil 2008; 20:113-118.
17. Kindt S, Coulie B, Wajs E, et al. Reproducibility and symptomatic predictors of a slow nutrient drinking test in health and in functional dyspepsia. Neurogastroenterol Motil 2008; 20:320-329.
18. Piessevaux H, Tack J, Walrand S, et al. Intragastric distribution of a standardized meal in health and functional dyspepsia: correlation with specific symptoms. Neurogastroenterol Motil 2003; 15:447-455.
19. Tominaga K, Higuchi K, Ochi M, et al. Concurrent assessment of reservoir and emptying of the stomach for dyspepsia patients. Hepatogastroenterology 2008; 55:744-749.
20. Cassilly DW, Wang YR, Friedenberg FK, et al. Symptoms of gastroparesis: use of the gastroparesis cardinal symptom index in symptomatic patients referred for gastric emptying scintigraphy. Digestion 2008; 78:144-151.
21. Bisschops R, Karamanolis G, Arts J, et al. Relationship between symptoms and ingestion of a meal in functional dyspepsia. Gut 2008; 57:1495-1503. This study demonstrates and quantifies how symptoms are triggered or aggravated by meal ingestion in the vast majority of dyspeptic patients.
22. van Lelyveld N, Schipper M, Samsom M. Lack of relationship between chronic upper abdominal symptoms and gastric function in functional dyspepsia. Dig Dis Sci 2008; 53:1223-1230.
23. Punkkinen J, FärkkiläM, Mätzke S, et al. Upper abdominal symptoms in patients with Type 1 diabetes: unrelated to impairment in gastric emptying caused by autonomic neuropathy. Diabet Med 2008; 25:570-577.
24. Kumar A, Attaluri A, Hashmi S, et al. Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis. Neurogastroenterol Motil 2008; 20:635-642.
25. Kojecky V, Bernatek J, Horowitz M, et al. Prevalence and determinants of delayed gastric emptying in hospitalised Type 2 diabetic patients. World J Gastroenterol 2008; 14:1564-1569.
26. Harrell SP, Studts JL, Dryden GW, et al. A novel classification scheme for gastroparesis based on predominant-symptom presentation. J Clin Gastroenterol 2008; 42:455-459.
27. Talley NJ, Locke GR, Lahr BD, et al. Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther 2006; 23:923-936.
28. Locke GR 3rd, Zinsmeister AR, Talley NJ, et al. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 2000; 75:907-912.
29. Holtmann G, Siffert W, Haag S, et al. G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004; 126:971-979.
30. Tahara T, Arisawa T, Shibata T, et al. Homozygous 825T allele of the GNB3 protein influences the susceptibility of Japanese to dyspepsia. Dig Dis Sci 2008; 53:642-646.
31. Tahara T, Arisawa T, Shibata T, et al. COMT gene val158met polymorphism in patients with dyspeptic symptoms. Hepatogastroenterology 2008; 55:979-982.
32. Arisawa T, Tahara T, Shibata T, et al. Genetic polymorphisms of cyclooxygenase-1 (COX-1) are associated with functional dyspepsia in Japanese women. J Womens Health (Larchmt) 2008; 17:1039-1043.
33. Tahara T, Arisawa T, Shibata T, et al. A genetic variant of the CD14 C-159T in patients with functional dyspepsia (FD) in Japanese subjects. J Clin Biochem Nutr 2008; 42:104-110.
34. Tahara T, Arisawa T, Shibata T, et al. Serotonin-2A receptor gene T102C polymorphism in patients with dyspeptic symptoms. Hepatogastroenterology 2008; 55:1921-1924.
35. Grudell AB, Camilleri M, Carlson P, et al. An exploratory study of the association of adrenergic and serotonergic genotype and gastrointestinal motor functions. Neurogastroenterol Motil 2008; 20:213-219.
36. Camilleri M, Carlson P, McKinzie S, et al. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am J Physiol Gastrointest Liver Physiol 2008; 294:G13-G19.
37. Ordög T. Interstitial cells of Cajal in diabetic gastroenteropathy. Neurogastroenterol Motil 2008; 20:8-18.
38. Zandecki M, Vanden Berghe P, Depoortere I, et al. Characterization of myenteric neuropathy in the jejunum of spontaneously diabetic BB-rats. Neurogastroenterol Motil 2008; 20:818-828.
39. Pasricha PJ, Pehlivanov ND, Gomez G, et al. Changes in the gastric enteric nervous system and muscle: a case report on two patients with diabetic gastroparesis. BMC Gastroenterol 2008; 8:21.
40. Hasler WL, Coleski R, Chey WD, et al. Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric retention. Am J Physiol Gastrointest Liver Physiol 2008; 294:G1384-G1391.
41. Mearin F, Pérez-Oliveras M, Perelló A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005; 129:98-104.
42. Saps M, Pensabene L, Di Martino L, et al. Postinfectious functional gastrointestinal disorders in children. J Pediatr 2008;152:812-816, 816.e1.
43. Rocco A, Sarnelli G, Compare D, et al. Tissue ghrelin level and gastric emptying rate in adult patients with celiac disease. Neurogastroenterol Motil 2008; 20:884-890.
44. Bassotti G, Villanacci V, Mazzocchi A, et al. Antroduodenojejunal motor activity in untreated and treated celiac disease patients. J Gastroenterol Hepatol 2008; 23 (7 Pt 2):e23-e28.
45. Pilichiewicz AN, Horowitz M, Holtmann GJ, et al. Relationship between symptoms and dietary patterns in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2009; 7:317-322.
46. Pilichiewicz AN, Feltrin KL, Horowitz M, et al. Functional dyspepsia is associated with a greater symptomatic response to fat but not carbohydrate, increased fasting and postprandial CCK, and diminished PYY. Am J Gastroenterol 2008; 103:2613-2623.
47. Schäppi MG, Borrelli O, Knafelz D, et al. Mast cell-nerve interactions in children with functional dyspepsia. J Pediatr Gastroenterol Nutr 2008; 47:472-480.
48. Lunding JA, Nordström LM, Haukelid AO, et al. Vagal activation by sham feeding improves gastric motility in functional dyspepsia. Neurogastroenterol Motil 2008; 20:618-624.
49. van Lelyveld N, Ter Linde J, Schipper M, Samsom M. Serotonergic signalling in the stomach and duodenum of patients with gastroparesis. Neurogastroenterol Motil 2008; 20:448-455.
50. Antiel RM, Risma JM, Grothe RM, et al. Orthostatic intolerance and gastrointestinal motility in adolescents with nausea and abdominal pain. J Pediatr Gastroenterol Nutr 2008; 46:285-288.
51. Boccia G, Buonavolontà R, Coccorullo P, et al. Dyspeptic symptoms in children: the result of a constipation-induced cologastric brake? Clin Gastroenterol Hepatol 2008; 6:556-560.
52. Sarnelli G, Vandenberghe J, Tack J. Visceral hypersensitivity in functional disorders of the upper gastrointestinal tract. Dig Liver Dis 2004; 36:371-376.
53. Tack J. Chemosensitivity of the human gastrointestinal tract in health and in disease. Neurogastroenterol Motil 2007; 19:241-244.
54. Hammer J, Führer M, Pipal L, Matiasek J. Hypersensitivity for capsaicin in patients with functional dyspepsia. Neurogastroenterol Motil 2008; 20:125-133. First study to establish and quantify enhanced visceral chemosensitivity in a subset of functional dyspepsia patients.
55. van den Elzen BD, Tytgat GN, Boeckxstaens GE. Gastric hypersensitivity induced by oesophageal acid infusion in healthy volunteers. Neurogastroenterol Motil 2009; 21:160-169.
56. Geeraerts B, Mimidis K, van Oudenhove L, et al. Role of endogenous opioids in the control of gastric sensorimotor function. Neurogastroenterol Motil 2008; 20:1094-1102. This study tested the hypothesis that impaired endogenous opioid pathways would contribute to the pathogenesis of visceral hypersensitivity. However, endogenous opioids seemed mainly involved in motor control.
57. Geeraerts B, Van Oudenhove L, Fischler B, et al. Influence of abuse history on gastric sensorimotor function in functional dyspepsia. Neurogastroenterol Motil 2009; 21:33-41.
58. Van Oudenhove L, Vandenberghe J, Geeraerts B, et al. Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation? Gut 2008; 57:1666-1673; Epub 2008 Jul 14. This assessed the relative contribution of central and peripheral mechanisms to symptom severity and weight loss in a large cohort of functional dyspepsia patients.
59. Röhm KD, Schö llhorn T, Boldt J, et al. Nutrition support and treatment of motility disorders in critically ill patients: results of a survey on German intensive care units. Eur J Anaesthesiol 2008; 25:58-66.
60. Landzinski J, Kiser TH, Fish DN, et al. Gastric motility function in critically ill patients tolerant vs. intolerant to gastric nutrition. JPEN J Parenter Enteral Nutr 2008; 32:45-50.
61. Chapman MJ, Fraser RJ, Bryant LK, et al. Gastric emptying and the organization of antro-duodenal pressures in the critically ill. Neurogastroenterol Motil 2008; 20:27-35.
62. Nguyen NQ, Fraser RJ, Bryant LK, et al. Diminished functional association between proximal and distal gastric motility in critically ill patients. Intensive Care Med 2008; 34:1246-1255.
63. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol 2008; 8:690-696.
64. Sugumar A, Singh A, Pasricha PJ. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol 2008; 6:726-733.
65. Sanger GJ, Alpers DH. Development of drugs for gastrointestinal motor disorders: translating science to clinical need. Neurogastroenterol Motil 2008; 20:177-184.
66. Sanger GJ. Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases. Drug Discov Today 2008; 13:234-239.
67. Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol 2008; 103:1906-1919. Report of two large phase three studies of tegaserod in functional dyspepsia. Although the studies show mixed efficacy results it provides valuable information for future trials in the assessment of different endpoints and severity-based subgroups of patients.
68. Holtmann G, Talley NJ, Liebregts T, et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006; 354:832-840.
69. Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008; 57:740-746. Report of 2 large phase 3 studies with itopride in functional dyspepsia. Although the studies are negative, the paper offers insights on the potential impact of strict exclusion of heartburn in functional dyspepsia trials.
70. Cellek S, Thangiah R, Jarvie EM, et al. Synergy between 5-HT4 receptor activation and acetylcholinesterase inhibition in human colon and rat forestomach. Neurogastroenterol Motil 2008; 20:539-545.
71. MacLaren R, Kiser TH, Fish DN, Wischmeyer PE. Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. JPEN J Parenter Enteral Nutr 2008; 32:412-419.
72. Ozaki K, Monnai M, Onoma M, et al. Effects of mitemcinal (GM-611), an orally active erythromycin-derived prokinetic agent, on delayed gastric emptying and postprandial glucose in a new minipig model of diabetes. J Diabetes Complications 2008; 22:339-347.
73. Onoma M, Ozaki K, Yogo K, et al. Mitemcinal (GM-611), an orally active motilin receptor agonist, improves delayed gastric emptying in a canine model of diabetic gastroparesis. Clin Exp Pharmacol Physiol 2008; 35:788-796.
74. Tack J, Depoortere I, Bisschops R, et al. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 2006; 55:327-333.
75. Tack J, Depoortere I, Bisschops R, et al. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther 2005; 22:847-853.
76. Akamizu T, Iwakura H, Ariyasu H, et al., FD Clinical Study Team. Repeated administration of ghrelin to patients with functional dyspepsia: its effects on food intake and appetite. Eur J Endocrinol 2008; 158:491-498.
77. Lasseter KC, Shaughnessy L, Cummings D, et al. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol 2008; 48:193-202.
78. Arts J, Holvoet L, Caenepeel P, et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther 2007; 26:1251-1258.
79. Friedenberg FK, Palit A, Parkman HP, et al. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol 2008; 103: 416-423. This paper, together with the preceding manuscript, confirms the unreliability of uncontrolled trials in motility disorders such as gastroparesis.
80. Van Oudenhove L, Kindt S, Vos R, et al. Influence of buspirone on gastric sensorimotor function in man. Aliment Pharmacol Ther 2008; 28:1326-1333.
81. Seto K, Sasaki T, Katsunuma K, et al. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil 2008; 20:1051-1059.
82. Madsen JL, Fuglsang S. A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans. Aliment Pharmacol Ther 2008; 27:609-615.
83. Talley NJ, Choung RS, Camilleri M, et al. Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. Aliment Pharmacol Ther 2008; 27:1122-1131.
84. Passos Mdo C, Duro D, Fregni F. CNS or classic drugs for the treatment of pain in functional dyspepsia? A systematic review and meta-analysis of the literature. Pain Physician 2008; 11:597-609.
85. Bouras EP, Talley NJ, Camilleri M, et al. Effects of amitriptyline on gastric sensorimotor function and postprandial symptoms in healthy individuals: a randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2008; 103:2043-2050.
86. Choung RS, Cremonini F, Thapa P, et al. The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trial. Neurogastroenterol Motil 2008; 20:220-227.
87. van Kerkhoven LA, Laheij RJ, Aparicio N, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebocontrolled trial. Clin Gastroenterol Hepatol 2008; 6:746-752. Large high quality study with an antidepressant in functional dyspepsia. No benefit over placebo was found.
88. Van Oudenhove L, Tack J. Is the antidepressant venlafaxine effective for the treatment of functional dyspepsia? Nat Clin Pract Gastroenterol Hepatol 2009; 6:74-75.
89. Hashash JG, Abdul-Baki H, Azar C, et al. Clinical trial: a randomized controlled cross-over study of flupenthixol+melitracen in functional dyspepsia. Aliment Pharmacol Ther 2008; 27:1148-1155.
90. IslamS, Vick LR, Runnels MJ, et al.Gastric electrical stimulation for children with intractable nausea and gastroparesis. J Pediatr Surg 2008; 43:437-442.
91. Sallam HS, Chen JD, Pasricha PJ. Feasibility of gastric electrical stimulation by percutaneous endoscopic transgastric electrodes. Gastrointest Endosc 2008; 68:754-759.
92. Maranki JL, Lytes V, Meilahn JE, et al. Predictive factors for clinical improvement with Enterra gastric electric stimulation treatment for refractory gastroparesis. Dig Dis Sci 2008; 53:2072-2078.
93. Lin Z, Hou Q, Sarosiek I, et al. Association between changes in symptoms and gastric emptying in gastroparetic patients treated with gastric electrical stimulation. Neurogastroenterol Motil 2008; 20:464-470.
94. Frøkjaer JB, Ejskjaer N, Rask P, et al. Central neuronal mechanisms of gastric electrical stimulation in diabetic gastroparesis. Scand J Gastroenterol 2008; 43:1066-1075.
95. Chen J, Koothan T, Chen JD. Synchronized gastric electrical stimulation improves vagotomy-induced impairment in gastric accommodation via the nitrergic pathway in dogs. Am J Physiol Gastrointest Liver Physiol 2009; 296: G310-G318.